RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Antibe Therapeutics Stock

Antibe Therapeutics ROA 2024

Antibe Therapeutics ROA

-0.28

Ticker

ATE.TO

ISIN

CA0370255097

WKN

A2QJPN

In 2024, Antibe Therapeutics's return on assets (ROA) was -0.28, a -1.78% increase from the -0.28 ROA in the previous year.

Antibe Therapeutics Aktienanalyse

What does Antibe Therapeutics do?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Antibe Therapeutics's Return on Assets (ROA)

Antibe Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Antibe Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Antibe Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Antibe Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Antibe Therapeutics stock

What is the Return on Assets (ROA) of Antibe Therapeutics this year?

The Return on Assets (ROA) of Antibe Therapeutics is -0.28 undefined this year.

What was the ROA of Antibe Therapeutics compared to the previous year?

The ROA of Antibe Therapeutics has increased by -1.78% compared to the previous year.

What consequences do high ROA have for investors of Antibe Therapeutics?

A high ROA is advantageous for investors of Antibe Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Antibe Therapeutics?

A low ROA can be unfavorable for investors of Antibe Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Antibe Therapeutics affect the company?

An increase in ROA of Antibe Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Antibe Therapeutics impact the company?

A reduction in the ROA of Antibe Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Antibe Therapeutics?

Some factors that can influence the ROA of Antibe Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Antibe Therapeutics important for investors?

The ROA of Antibe Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Antibe Therapeutics take to improve ROA?

To improve ROA, Antibe Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Antibe Therapeutics pay?

Over the past 12 months, Antibe Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antibe Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Antibe Therapeutics?

The current dividend yield of Antibe Therapeutics is .

When does Antibe Therapeutics pay dividends?

Antibe Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antibe Therapeutics?

Antibe Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Antibe Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antibe Therapeutics located?

Antibe Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antibe Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antibe Therapeutics from 11/10/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/10/2024.

When did Antibe Therapeutics pay the last dividend?

The last dividend was paid out on 11/10/2024.

What was the dividend of Antibe Therapeutics in the year 2023?

In the year 2023, Antibe Therapeutics distributed 0 CAD as dividends.

In which currency does Antibe Therapeutics pay out the dividend?

The dividends of Antibe Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Antibe Therapeutics

Our stock analysis for Antibe Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antibe Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.